November 2, 2026StocksTechnology·Bullish·regulatory

FDA clears IND for epetraborole in polycythemia vera; Phase 2 trial to start Q4 2026

AN2 Therapeutics says the FDA cleared its investigational new drug application for epetraborole in polycythemia vera, with a Phase 2 trial to start in Q4 2026.

Detected & updated continuously · Source: Nebula

Story subjects

AN2 Therapeutics, Inc.Food and Drug Administration

Track sentiment and mindshare across stocks and crypto in Nebula.

Open Nebula